| PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia BS Hanna, PM Roessner, A Scheffold, BMC Jebaraj, Y Demerdash, ... Leukemia 33 (6), 1427-1438, 2019 | 67 | 2019 |
| IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia A Scheffold, BMC Jebaraj, E Tausch, J Bloehdorn, P Ghia, A Yahiaoui, ... Blood, The Journal of the American Society of Hematology 134 (6), 534-547, 2019 | 64 | 2019 |
| BRAF mutations in chronic lymphocytic leukemia BMC Jebaraj, D Kienle, A Bühler, D Winkler, H Döhner, S Stilgenbauer, ... Leukemia & lymphoma 54 (6), 1177-1182, 2013 | 63 | 2013 |
| Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model A Scheffold, IR Holtman, S Dieni, N Brouwer, SF Katz, BMC Jebaraj, ... Acta neuropathologica communications 4, 1-17, 2016 | 51 | 2016 |
| Telomere dysfunction and chromothripsis A Ernst, DTW Jones, KK Maass, A Rode, KI Deeg, BMC Jebaraj, ... International journal of cancer 138 (12), 2905-2914, 2016 | 51 | 2016 |
| Venetoclax: targeting BCL2 in hematological cancers A Scheffold, BMC Jebaraj, S Stilgenbauer Small Molecules in Hematology, 215-242, 2018 | 46 | 2018 |
| Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 E Tausch, P Beck, RF Schlenk, BMC Jebaraj, A Dolnik, DY Yosifov, ... haematologica 105 (10), 2440, 2020 | 44 | 2020 |
| Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription J Edelmann, K Holzmann, E Tausch, EA Saunderson, BMC Jebaraj, ... Haematologica 105 (5), 1379, 2020 | 36 | 2020 |
| Whole-exome sequencing revealed no recurrent mutations within the PI3K pathway in relapsed chronic lymphocytic leukemia patients progressing under idelalisib treatment P Ghia, V Ljungstroem, E Tausch, A Agathangelidis, A Scheffold, L Scarfo, ... Blood, The Journal of the American Society of Hematology 128 (22), 2770-2770, 2016 | 33 | 2016 |
| Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL DY Yosifov, I Idler, N Bhattacharya, M Reichenzeller, V Close, D Ezerina, ... Leukemia 34 (1), 115-127, 2020 | 29 | 2020 |
| Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia BMC Jebaraj, A Müller, RP Dheenadayalan, S Endres, PM Roessner, ... Blood, The Journal of the American Society of Hematology 139 (6), 859-875, 2022 | 23 | 2022 |
| Telomere length in mantle cell lymphoma BMC Jebaraj, D Kienle, A Lechel, D Mertens, M Heuberger, G Ott, ... Blood, The Journal of the American Society of Hematology 121 (7), 1184-1187, 2013 | 22 | 2013 |
| Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia BMC Jebaraj, E Tausch, DA Landau, J Bahlo, S Robrecht, ... Leukemia 33 (9), 2183-2194, 2019 | 21 | 2019 |
| Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome D Steinbrecher, BMC Jebaraj, C Schneider, J Edelmann, F Cymbalista, ... Leukemia & lymphoma 59 (7), 1614-1623, 2018 | 20 | 2018 |
| Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia J Bloehdorn, A Braun, A Taylor-Weiner, BMC Jebaraj, S Robrecht, ... Nature Communications 12 (1), 5395, 2021 | 19 | 2021 |
| Reconstruction of rearranged T‐cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T‐cell prolymphocytic leukemia P Patil, A Cieslak, SH Bernhart, UH Toprak, R Wagener, C Lopez, ... Genes, Chromosomes and Cancer 59 (4), 261-267, 2020 | 18 | 2020 |
| Telomere dysfunction in chronic lymphocytic leukemia BMC Jebaraj, S Stilgenbauer Frontiers in Oncology 10, 612665, 2021 | 16 | 2021 |
| Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors J Qi, S Endres, DY Yosifov, E Tausch, RP Dheenadayalan, X Gao, ... Blood Advances 7 (19), 5698-5702, 2023 | 10 | 2023 |
| Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations E Tausch, V Ljungström, A Agathangelidis, M Zapatka, L Scarfò, ... Blood, The Journal of the American Society of Hematology 139 (22), 3340-3344, 2022 | 10 | 2022 |
| Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia C Bruedigam, AH Porter, A Song, G Vroeg in de Wei, T Stoll, J Straube, ... Nature Cancer 5 (1), 47-65, 2024 | 9 | 2024 |
